188 related articles for article (PubMed ID: 38234841)
1. Wnt inhibition alleviates resistance to immune checkpoint blockade in glioblastoma.
Jain R; Krishnan S; Lee S; Amoozgar Z; Subudhi S; Kumar A; Posada J; Lindeman N; Lei P; Duquette M; Roberge S; Huang P; Andersson P; Datta M; Munn L; Fukumura D
Res Sq; 2023 Dec; ():. PubMed ID: 38234841
[TBL] [Abstract][Full Text] [Related]
2. TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma.
Raphael I; Kumar R; McCarl LH; Shoger K; Wang L; Sandlesh P; Sneiderman CT; Allen J; Zhai S; Campagna ML; Foster A; Bruno TC; Agnihotri S; Hu B; Castro BA; Lieberman FS; Broniscer A; Diaz AA; Amankulor NM; Rajasundaram D; Pollack IF; Kohanbash G
Front Immunol; 2021; 12():637146. PubMed ID: 34025646
[TBL] [Abstract][Full Text] [Related]
3. Distinct Cell Adhesion Signature Defines Glioblastoma Myeloid-Derived Suppressor Cell Subsets.
Bayik D; Bartels CF; Lovrenert K; Watson DC; Zhang D; Kay K; Lee J; Lauko A; Johnson S; Lo A; Silver DJ; McGraw M; Grabowski M; Mohammadi AM; Veglia F; Fan Y; Vogelbaum MA; Scacheri P; Lathia JD
Cancer Res; 2022 Nov; 82(22):4274-4287. PubMed ID: 36126163
[TBL] [Abstract][Full Text] [Related]
4. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas.
Flores-Toro JA; Luo D; Gopinath A; Sarkisian MR; Campbell JJ; Charo IF; Singh R; Schall TJ; Datta M; Jain RK; Mitchell DA; Harrison JK
Proc Natl Acad Sci U S A; 2020 Jan; 117(2):1129-1138. PubMed ID: 31879345
[TBL] [Abstract][Full Text] [Related]
5. Blocking Wnt/β-catenin Signal Amplifies Anti-PD-1 Therapeutic Efficacy by Inhibiting Tumor Growth, Migration, and Promoting Immune Infiltration in Glioblastomas.
Zhang H; Bi Y; Wei Y; Liu J; Kuerban K; Ye L
Mol Cancer Ther; 2021 Jul; 20(7):1305-1315. PubMed ID: 34001635
[TBL] [Abstract][Full Text] [Related]
6. Radiotherapy, Temozolomide, and Antiprogrammed Cell Death Protein 1 Treatments Modulate the Immune Microenvironment in Experimental High-Grade Glioma.
Riva M; Wouters R; Sterpin E; Giovannoni R; Boon L; Himmelreich U; Gsell W; Van Ranst M; Coosemans A
Neurosurgery; 2021 Jan; 88(2):E205-E215. PubMed ID: 33289503
[TBL] [Abstract][Full Text] [Related]
7. UBE2T Promotes Temozolomide Resistance of Glioblastoma Through Regulating the Wnt/β-Catenin Signaling Pathway.
Wang Y; Gao G; Wei X; Zhang Y; Yu J
Drug Des Devel Ther; 2023; 17():1357-1369. PubMed ID: 37181827
[TBL] [Abstract][Full Text] [Related]
8. Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy.
Schetters STT; Rodriguez E; Kruijssen LJW; Crommentuijn MHW; Boon L; Van den Bossche J; Den Haan JMM; Van Kooyk Y
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690667
[TBL] [Abstract][Full Text] [Related]
9. Myeloid-Derived Suppressor Cell Subsets Drive Glioblastoma Growth in a Sex-Specific Manner.
Bayik D; Zhou Y; Park C; Hong C; Vail D; Silver DJ; Lauko A; Roversi G; Watson DC; Lo A; Alban TJ; McGraw M; Sorensen M; Grabowski MM; Otvos B; Vogelbaum MA; Horbinski C; Kristensen BW; Khalil AM; Hwang TH; Ahluwalia MS; Cheng F; Lathia JD
Cancer Discov; 2020 Aug; 10(8):1210-1225. PubMed ID: 32300059
[TBL] [Abstract][Full Text] [Related]
10. Reprogramming the immunosuppressive microenvironment of IDH1 wild-type glioblastoma by blocking Wnt signaling between microglia and cancer cells.
Fan D; Yue Q; Chen J; Wang C; Yu R; Jin Z; Yin S; Wang Q; Chen L; Liao X; Peng C; Zhang J; Cao Z; Mao Y; Huang R; Chen L; Li C
Oncoimmunology; 2021 Jun; 10(1):1932061. PubMed ID: 34123575
[TBL] [Abstract][Full Text] [Related]
11. CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients.
Dubinski D; Wölfer J; Hasselblatt M; Schneider-Hohendorf T; Bogdahn U; Stummer W; Wiendl H; Grauer OM
Neuro Oncol; 2016 Jun; 18(6):807-18. PubMed ID: 26578623
[TBL] [Abstract][Full Text] [Related]
12. Myeloid derived suppressor cell infiltration of murine and human gliomas is associated with reduction of tumor infiltrating lymphocytes.
Raychaudhuri B; Rayman P; Huang P; Grabowski M; Hambardzumyan D; Finke JH; Vogelbaum MA
J Neurooncol; 2015 Apr; 122(2):293-301. PubMed ID: 25579983
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the Wnt/β-catenin pathway enhances antitumor immunity in ovarian cancer.
Doo DW; Meza-Perez S; Londoño AI; Goldsberry WN; Katre AA; Boone JD; Moore DJ; Hudson CT; Betella I; McCaw TR; Gangrade A; Bao R; Luke JJ; Yang ES; Birrer MJ; Starenki D; Cooper SJ; Buchsbaum DJ; Norian LA; Randall TD; Arend RC
Ther Adv Med Oncol; 2020; 12():1758835920913798. PubMed ID: 32313567
[TBL] [Abstract][Full Text] [Related]
14. Combination with TMZ and miR-505 inhibits the development of glioblastoma by regulating the WNT7B/Wnt/β-catenin signaling pathway.
Zhang C; Yang X; Fu C; Liu X
Gene; 2018 Sep; 672():172-179. PubMed ID: 29906532
[TBL] [Abstract][Full Text] [Related]
15. Manipulating the Wnt/β-catenin signaling pathway to promote anti-tumor immune infiltration into the TME to sensitize ovarian cancer to ICB therapy.
Wall JA; Meza-Perez S; Scalise CB; Katre A; Londoño AI; Turbitt WJ; Randall T; Norian LA; Arend RC
Gynecol Oncol; 2021 Jan; 160(1):285-294. PubMed ID: 33168307
[TBL] [Abstract][Full Text] [Related]
16. DNA methylation and protein expression of Wnt pathway markers in progressive glioblastoma.
Tompa M; Kajtar B; Galik B; Gyenesei A; Kalman B
Pathol Res Pract; 2021 Jun; 222():153429. PubMed ID: 33857857
[TBL] [Abstract][Full Text] [Related]
17. Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape.
Takeuchi Y; Tanegashima T; Sato E; Irie T; Sai A; Itahashi K; Kumagai S; Tada Y; Togashi Y; Koyama S; Akbay EA; Karasaki T; Kataoka K; Funaki S; Shintani Y; Nagatomo I; Kida H; Ishii G; Miyoshi T; Aokage K; Kakimi K; Ogawa S; Okumura M; Eto M; Kumanogoh A; Tsuboi M; Nishikawa H
Sci Immunol; 2021 Nov; 6(65):eabc6424. PubMed ID: 34767457
[TBL] [Abstract][Full Text] [Related]
18. Crosstalk between β-Catenin and CCL2 Drives Migration of Monocytes towards Glioblastoma Cells.
Aretz P; Maciaczyk D; Yusuf S; Sorg RV; Hänggi D; Liu H; Liu H; Dakal TC; Sharma A; Bethanabatla R; Neumann S; Maciaczyk J
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35562953
[TBL] [Abstract][Full Text] [Related]
19. LINC00511 facilitates Temozolomide resistance of glioblastoma cells via sponging miR-126-5p and activating Wnt/β-catenin signaling.
Lu Y; Tian M; Liu J; Wang K
J Biochem Mol Toxicol; 2021 Sep; 35(9):e22848. PubMed ID: 34328678
[TBL] [Abstract][Full Text] [Related]
20. Wnt/β-catenin signaling is a key downstream mediator of MET signaling in glioblastoma stem cells.
Kim KH; Seol HJ; Kim EH; Rheey J; Jin HJ; Lee Y; Joo KM; Lee J; Nam DH
Neuro Oncol; 2013 Feb; 15(2):161-71. PubMed ID: 23258844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
